- United States
- /
- Medical Equipment
- /
- NasdaqCM:NSPR
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023)
InspireMD (NASDAQ:NSPR) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$1.81m (up 16% from 3Q 2023).
- Net loss: US$7.89m (loss widened by 52% from 3Q 2023).
- US$0.16 loss per share (further deteriorated from US$0.15 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
InspireMD Earnings Insights
Looking ahead, revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 7.1% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for InspireMD (1 is a bit concerning!) that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NSPR
InspireMD
A medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific.
Flawless balance sheet low.